Gilead said it will partner with Sangamo Therapeutics to use its gene-editing technology to develop off-the-shelf and personalized chimeric antigen receptor T-cell therapies. Sangamo will receive $150 million in cash upfront and and a little over $3 billion in milestone payments.
Dynavax Technologies secured a $175 million loan to be used for its hepatitis B vaccine Heplisav-B's marketing launch and to finance its immuno-oncology trials. Heplisav-B, which gained full support from the CDC's Advisory Committee on Immunization Practices, is the only two-dose vaccine for adults in the US for the prevention of HBV infections.
The Kenya Agricultural and Livestock Research Organization has developed biotech corn seeds called DroughtTEGO that are resistant to drought and pests including fall armyworms and stalk and stem borers, which pose challenges to the country's farmers.
Apple is moving to help patients gather their health records into one place accessible via their iPhones. The move could have implications for pharma marketers, from possibly gaining access to consumers' health data and patients opting in to supply anonymized data themselves to gaining a direct line to patients.
Havas Health & You has launched a new agency, Havas Health Plus, that will use algorithms and analysis to explore the emotional drivers behind health decisions. "With all the emotions involved with health care decisions, we felt this was a huge opportunity to unearth," said Donna Murphy, global CEO of Havas Health & You.
The $17.3 million acquisition of Dextera Surgical was completed by B. Braun subsidiary Aesculap -- a move that expands its portfolio of products for beating heart coronary and video-assisted thoracic surgery. Aesculap will manage Dextera's Redwood City, Calif., operations for continued manufacturing and distribution of Dextera's surgical products.
A partnership was reached by the American Cancer Society and Atlanta-based Global Center for Medical Innovation in hopes of raising $5 million for reducing the time and cost of advancing new ideas from ACS-funded research to market. The center intends to bring together investors, research centers, universities and other members of the medtech community, while three to five projects will be selected as focus of the partnership every year.
Evinance Innovation, a clinical decision support software company, was acquired by Varian Medical Systems to strengthen Varian's 360 Oncology care management platform, which is designed for providing oncology teams with cancer guidelines and adherence tools and point-of-care clinical decision information. Financial terms were not disclosed.
Movi agreed to become the exclusive distribution partner of Valeritas for commercializing the Valeritas' V-Go wearable insulin delivery device in Italy. Under the deal, Valeritas will maintain its responsibility for the development, regulatory approval and manufacturing of the product, while Movi will be in charge of marketing and sales.
A Market Research Future report predicts the worldwide market for spinal implants will see a 6.6% compound annual growth rate through 2022 because of the growing popularity of minimally invasive spine surgery. Key players in the market, which is dominated by the US, include DePuy Synthes, Exactech, Integra LifeSciences, K2M, Medtronic, Nuvasive, Stryker and Zimmer Biomet.